A retrospective observational study of patients with melanoma prescribed combined BRAF and MEK inhibitors in a real-world treatment setting in Japan  

作　　者：Kenjiro Namikawa Kok Yew Ngew Zuzanna Lukowicz Ryosuke Kano 

机构地区：[1]Department of Dermatologic Oncology,National Cancer Hospital,Tokyo,Japan [2]Real World Evidence Department,Novartis Corporation(Malaysia)Sdn.Bhd.,Petaling Jaya,Malaysia [3]RWE&Biostatistics,Putnam PHMR,Kraków,Poland [4]Medical Affairs Division,Novartis Pharma K.K.,Tokyo,Japan

出　　处：《Malignancy Spectrum》2024年第4期312-322,共11页肿瘤学全景(英文)

基　　金：funded by Novartis Japan,which developed and marketed TKIs for the treatment of melanoma.

摘　　要：Objective:This study aimed to describe patients with melanoma initiating treatments with dabrafenib plus trametinib(Dab+Tram)or encorafenib plus binimetinib(Enco+Bini)in a real-world setting in Japan.Methods:Data were extracted from the Japanese Medical Data Vision(MDV)insurance claims database.Patients diagnosed with melanoma between 2012 and 2021 and prescribed with Dab+Tram or Enco+Bini were included in three cohorts:non-adjuvant Dab+Tram,adjuvant Dab+Tram,and Enco+Bini.Data were extracted on patient characteristics at treatment initiation.During follow-up,all changes in melanoma treatments were documented.Treatment adherence was determined as the proportion of prescription days covered(PDC)and treatment dose intensity as the relative dose intensity(RDI).Results:Sixty-seven patients were included in the non-adjuvant Dab+Tram cohort(55 first-line treatments),seven in the adjuvant Dab+Tram cohort(six first-line treatments),and 16 in the Enco+Bini cohort(four firstline treatments).The mean age was 61.3±13.5 years and 56.1%were men.Twenty-seven patients with non-adjuvant Dab+Tram or Enco+Bini in first line(45.8%)switched to a second line.The median treatment duration was 11.8 months for Dab+Tram and 8.1 months for Enco+Bini.A PDC≥80%was observed for 85.7%of patients with adjuvant Dab+Tram,68.7%for non-adjuvant Dab+Tram,and 75.0%for Enco+Bini.Median RDI was 1.0 for adjuvant Dab+Tram,0.9 for non-adjuvant Dab+Tram,and 0.6 for Enco+Bini.Conclusion:Dab+Tram is used consistently with clinical practice guidelines in the adjuvant setting,but adherence in the non-adjuvant setting is suboptimal,as is the prescribed dose of Enco+Bini.Prescribers should ensure that these therapies are used in an optimal way to improve outcomes in melanoma.

关 键 词：BRAF medication use MEK MELANOMA targeted kinase inhibitor 

分 类 号：R739.5[医药卫生—肿瘤]